BRPI0518777A2 - usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx) - Google Patents

usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)

Info

Publication number
BRPI0518777A2
BRPI0518777A2 BRPI0518777-0A BRPI0518777A BRPI0518777A2 BR PI0518777 A2 BRPI0518777 A2 BR PI0518777A2 BR PI0518777 A BRPI0518777 A BR PI0518777A BR PI0518777 A2 BRPI0518777 A2 BR PI0518777A2
Authority
BR
Brazil
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
BRPI0518777-0A
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518777(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of BRPI0518777A2 publication Critical patent/BRPI0518777A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

USOS DE UM AGONISTA DO RECEPTOR DE ADENOSINA A3 (A3AR) E DE METOTREXATO (MTX). A presente invenção diz respeito ao tratamento terapêutico de condições inflamatórias por uma administração combinada de metotrexato e um agonista do receptor de adenosina A3. São fornecidos métodos de tratamento terapêutico que compreende uma tal administração combinada, composições farmacêuticas úteis em tais métodos que compreende o uso de um agonista do receptor de adenosina A3 ou metotrexato, bem como o uso de qualquer um destes agentes ativos para a preparação de uma tal composição farmacêutica.
BRPI0518777-0A 2004-12-02 2005-11-30 usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx) BRPI0518777A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001280 WO2006059328A1 (en) 2004-12-02 2005-11-30 Treatment of inflammation

Publications (1)

Publication Number Publication Date
BRPI0518777A2 true BRPI0518777A2 (pt) 2008-12-09

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0518777-0A BRPI0518777A2 (pt) 2004-12-02 2005-11-30 usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)
BRPI0518795-8A BRPI0518795A2 (pt) 2004-12-02 2005-11-30 mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0518795-8A BRPI0518795A2 (pt) 2004-12-02 2005-11-30 mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio

Country Status (13)

Country Link
US (3) US20080056992A1 (pt)
EP (2) EP1817079B1 (pt)
JP (2) JP4842964B2 (pt)
KR (2) KR20070090222A (pt)
AT (2) ATE402739T1 (pt)
AU (2) AU2005310873B2 (pt)
BR (2) BRPI0518777A2 (pt)
CA (2) CA2586773C (pt)
DE (2) DE602005008639D1 (pt)
DK (1) DK1817079T3 (pt)
ES (2) ES2309817T3 (pt)
MX (2) MX2007006500A (pt)
WO (2) WO2006059327A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
JP5339916B2 (ja) * 2005-11-30 2013-11-13 キャン−ファイト・バイオファーマ・リミテッド 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
US9102698B2 (en) 2007-03-14 2015-08-11 Can-Fite Biopharma Ltd. Process for the synthesis of IB-MECA
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
MX2012010006A (es) * 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
WO2011158904A1 (ja) * 2010-06-18 2011-12-22 株式会社林原生物化学研究所 アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61502124A (ja) 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− 免疫応答の調節方法
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
EP1554574A2 (en) * 2002-10-21 2005-07-20 Can-Fite Biopharma Ltd. Diagnostic markers for therapeutic treatment
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
EP1554583B1 (en) * 2002-10-22 2007-08-22 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a disease state
US7141553B2 (en) * 2002-11-19 2006-11-28 Can-Fite Biopharma Ltd. Israel A3AR agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
AR044927A1 (es) 2003-06-25 2005-10-12 Elan Pharm Inc Metodos y composiciones para tratar la artritis reumatoidea
DE602004006895T2 (de) 2003-12-29 2008-01-31 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
EP1817589B1 (en) 2009-06-24
DK1817079T3 (da) 2008-11-17
ATE434762T1 (de) 2009-07-15
US20100256084A1 (en) 2010-10-07
KR20070100261A (ko) 2007-10-10
EP1817589A1 (en) 2007-08-15
KR20070090222A (ko) 2007-09-05
US20130345163A1 (en) 2013-12-26
JP2008522182A (ja) 2008-06-26
CA2586774A1 (en) 2006-06-08
EP1817079B1 (en) 2008-07-30
EP1817079A1 (en) 2007-08-15
WO2006059327A1 (en) 2006-06-08
BRPI0518795A2 (pt) 2008-12-09
AU2005310874B2 (en) 2008-11-27
AU2005310874A1 (en) 2006-06-08
CA2586773A1 (en) 2006-06-08
ES2309817T3 (es) 2008-12-16
US20080056992A1 (en) 2008-03-06
DE602005015135D1 (de) 2009-08-06
WO2006059328A1 (en) 2006-06-08
JP2008521883A (ja) 2008-06-26
US8541182B2 (en) 2013-09-24
ES2327435T3 (es) 2009-10-29
JP4842964B2 (ja) 2011-12-21
AU2005310873A1 (en) 2006-06-08
MX2007006501A (es) 2007-07-13
DE602005008639D1 (de) 2008-09-11
ATE402739T1 (de) 2008-08-15
CA2586773C (en) 2018-03-27
MX2007006500A (es) 2007-07-13
AU2005310873B2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
BRPI0518777A2 (pt) usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)
WO2006065987A3 (en) Systems and methods of light-scattering based in vivo flow cytometry
WO2008041953A3 (en) Dengue diagnosis and treatment
EP1447665A3 (en) Method for reducing effect of hematocrit on measurement of an analyte in whole blood, and test kit and test article useful in the method
ATE530635T1 (de) Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
PL2129391T3 (pl) Metoda diagnostyczna
EP3185013A3 (en) Biomarkers for determining an allograft tolerant phenotype
EP1884778A4 (en) METHOD FOR TESTING THE EFFECTIVENESS OF ANTITHROMBOTIC AGENT
Wray et al. Hepcidin detects iron deficiency in S ri L ankan adolescents with a high burden of hemoglobinopathy: A diagnostic test accuracy study
Heerasing et al. Does lymphopenia or macrocytosis reflect 6‐thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6‐mercaptopurine?
WO2005070086A3 (en) Methods and compositions for determining a graft tolerant phenotype in a subject
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
BRPI0512948A (pt) biomarcadores de mal de alzheimer
AR043398A1 (es) Metodos de determinacion de un regimen quimioterapeutico basado en la perdida de heterocigosidad en el lugar de timidilato sintasa
WO2002080960A3 (en) Treatment of neuropathologies associated with expression of tnf-alpha
WO2003077875A3 (en) Proteins associated with growth, differentiation, and death
BR0209172A (pt) Método de detecção de doenças induzidas por glúten em uma amostra sanguìnea de um indivìduo, e kit teste para uso no método
Plattner et al. Pharmacology of ciliated protozoa—drug (in) sensitivity and experimental drug (ab) use
WO2011113942A3 (en) Method for predicting the responsiveness to chemotherapy
Canini et al. A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor
WO2004031364A3 (en) Proteins associated with cell growth, differentiation, and death
Seither et al. Interconversion of tetrahydrofolate cofactors to dihydrofolate induced by trimetrexate after suppression of thymidylate synthase by fluorodeoxyuridine in L1210 leukemia cells
WO2003095622A8 (en) Proteins associated with cell growth, differentiation, and death

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.